Does not cound like ... there will be compensation or additional to Urocidin wasted on the failed/ stopped first attempt for the P3B trial. BNC will have to eat the manufacturing cost! (for Endo's screw up.)
Here is the reply on my follow-up letter after a call to Jennifer. You guys draw the conclusion.
Hi, Jennifer
Thank you for taking my call yesterday. Due to the limited time, I forgot to ask the two remaining questions. I hope you could help clarify them.
1. Since the original contract of milestone payments was for a certain supply amount of Urocidin for the P3b trial. Now that the trial has been aborted and new trial needs to be done. That means more than the original estimated amount of Urocidin will be needed. Is BNC going to be reimbursed for the additional supply via a new milestone payment contract?
A: I cannot comment on the milestones in our agreement with Endo as these are not publicly disclosed. I can say that the agreement involves Bioniche being responsible for manufacturing both clinical trial material and commercial product, in return for a percentage of the net selling price wherever the product is sold.
2. Is Endo still trying to test Urocidin as a refractory drug in the new trial?
A: As for the clinical plan for Urocidin going forward, this will be revealed when it is decided upon by ourselves and Endo.
Thanks for your attention again,